Welcome to the ePoster Viewing Panel of AICOG 2025

Invasive mole, a rare but aggressive form of gestational trophoblastic disease (GTD), is characterized by the infiltration of trophoblastic tissue into the myometrium or beyond. This condition often arises after a molar pregnancy but can also follow other gestational events. Prompt diagnosis and treatment are crucial to prevent complications, such as uterine rupture, hemorrhage, or metastasis. This report presents a case of invasive mole successfully treated with EMACO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, and vincristine) chemotherapy. The patient, a 29-year-old woman, presented with irregular vaginal bleeding and elevated beta-human chorionic gonadotropin (?-hCG) levels following a dilatation and curettage procedure for a prior molar pregnancy. Ultrasonography and magnetic resonance imaging confirmed a diagnosis of invasive mole with uterine invasion but no distant metastases. Initial single-agent chemotherapy with methotrexate failed to adequately reduce ?-hCG levels, necessitating a switch to multi-agent EMACO therapy. The patient responded favorably, with ?-hCG normalization achieved within six cycles. Follow-up imaging showed complete resolution of the uterine mass. No significant adverse effects were observed, and the patient has remained in remission for 12 months post-treatment. This case highlights the effectiveness of EMACO therapy in treating invasive mole, particularly in high-risk or refractory cases. It underscores the importance of individualized treatment protocols, close monitoring of ?-hCG levels, and a multidisciplinary approach to optimize patient outcomes.